Management of Nodular Lymphocyte-Predominant Hodgkin Lymphoma

News
Video
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

In this video reviews the management of nodular lymphocyte-predominant Hodgkin lymphoma.

In this video, Dennis A. Eichenauer, MD, of the University of Cologne, Germany, reviews the management of nodular lymphocyte-predominant Hodgkin lymphoma.

Eichenauer gave a presentation on this topic, “Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Unique Disease Deserving Unique Management,” during an education session at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.

 

Recent Videos
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Related Content
BMT CTN 1902: Post-transplant Consolidation is Back, and This Time With CAR-T!

BMT CTN 1902: Post-transplant Consolidation is Back, and This Time With CAR-T!

American Society for Transplantation and Cellular Therapy
March 3rd 2025
Article

Overall, BMT CTN 0702 showed no improvement in outcomes with added post-ASCT consolidation as compared to standard lenalidomide maintenance.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD
February 17th 2025
Podcast

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Data from the phase 3 STARGLO study support the CHMP’s recommendation for approving glofitamab plus gemcitabine/oxaliplatin in relapsed/refractory DLBCL.

CHMP Recommends EU Approval for Glofitamab Combination in R/R DLBCL

Russ Conroy
February 28th 2025
Article

Data from the phase 3 STARGLO study support the CHMP’s recommendation for approving glofitamab plus gemcitabine/oxaliplatin in relapsed/refractory DLBCL.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MBA, MSc
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Tambiciclib/Zanubrutinib Yields Promising Responses in R/R DLBCL

Tambiciclib/Zanubrutinib Yields Promising Responses in R/R DLBCL

Tim Cortese
February 21st 2025
Article

Tambiciclib plus zanubrutinib doubled the expected ORR of zanubrutinib monotherapy, eliciting an ORR of 67% in patients with relapsed or refractory DLBCL.

3 Things You Should Know About Adverse Events With Targeted Therapies for DLBCL

3 Things You Should Know About Adverse Events With Targeted Therapies for DLBCL

ONCOLOGY Staff
February 20th 2025
Article

Tips from experts on how to think about and manage adverse events in patients with diffuse large B-cell lymphoma.